Omistat (Simvastatin)

Simvastatin, the active ingredient in Omistat, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels in adults at risk of cardiovascular disease. GNH USA supplies Omistat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omistat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omistat (simvastatin) acts on lipid metabolism pathways to reduce cholesterol synthesis.

- Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol. - Familial hypercholesterolaemia (heterozygous): improves lipid profile and reduces cardiovascular risk. - Primary prevention of cardiovascular disease: decreases the incidence of myocardial infarction, stroke and related events in at‑risk adults.

Simvastatin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Muscle aches or tenderness. - Headache. - Nausea or abdominal discomfort. - Elevated liver enzymes. - Diarrhea.

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown). - Acute liver injury. - Severe allergic reactions such as angioedema. - Myopathy with marked CK elevation. - Stevens‑Stevenson skin rash. - Hepatotoxicity with jaundice.

When prescribing Omistat, clinicians should consider several safety aspects.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Drug‑drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Renal impairment: adjust therapy in patients with severe kidney disease. - Pregnancy and lactation: contraindicated due to potential fetal harm. - Myopathy risk: evaluate for muscle symptoms, especially with high‑intensity dosing. - Store at below 25°C: keep in the original container, protect from moisture and light.

Simvastatin interacts with several medicines that affect its metabolism and safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). - Gemfibrozil and other fibrates: increased risk of myopathy. - Danirun (DAN‑      ).

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may require INR monitoring. - Calcium channel blockers (amlodipine, verapamil): may increase simvastatin levels. - Digoxin: monitor for enhanced effects. - St.   .